LV11103A - Perorali lietojama zalu forma centralas nervu sistemas dofamina deficita stavoklu arstesanai - Google Patents

Perorali lietojama zalu forma centralas nervu sistemas dofamina deficita stavoklu arstesanai

Info

Publication number: LV11103A
Authority: LV; Latvia
Prior art keywords: weight; pct; parts; dofamina; nervous system
Prior art date: 1991-01-23

Application number

LV930567A

Other languages

English (en)

Other versions

LV11103B (en

Inventor

Udo Wenzel

Guenther Weber

Juergen Metzner

Alfred Darr

Sabine Freitag

Frank-Ulrich Floether

Frank-Michael Albert

Margit Haase

Edith Leistner

Original Assignee

Isis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-23

Filing date

1993-06-14

Publication date

1996-04-20

1993-06-14 Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh

1996-04-20 Publication of LV11103A publication Critical patent/LV11103A/lv

1996-06-20 Publication of LV11103B publication Critical patent/LV11103B/lv

Links

230000007812 deficiency Effects 0.000 title abstract 2
210000003169 central nervous system Anatomy 0.000 title 1
239000004372 Polyvinyl alcohol Substances 0.000 abstract 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
229920002959 polymer blend Polymers 0.000 abstract 2
229920002451 polyvinyl alcohol Polymers 0.000 abstract 2
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
229960004205 carbidopa Drugs 0.000 abstract 1
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
229960003638 dopamine Drugs 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000013583 drug formulation Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229960004502 levodopa Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000011148 porous material Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LVP-93-567A 1991-01-23 1993-06-14 Oraly administerable drugs for the treatment of central dopamine deficiency conditions LV11103B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4101873A DE4101873C2 (de)	1991-01-23	1991-01-23	Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
PCT/DE1992/000043 WO1992012710A1 (de)	1991-01-23	1992-01-23	Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustände

Publications (2)

Publication Number	Publication Date
LV11103A true LV11103A (lv)	1996-04-20
LV11103B LV11103B (en)	1996-06-20

Family

ID=6423528

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-93-567A LV11103B (en)	1991-01-23	1993-06-14	Oraly administerable drugs for the treatment of central dopamine deficiency conditions

Country Status (22)

Country	Link
US (1)	US5532274A (lv)
EP (1)	EP0568577B1 (lv)
JP (1)	JP3382940B2 (lv)
AT (1)	ATE147264T1 (lv)
AU (1)	AU658171B2 (lv)
BG (1)	BG61677B1 (lv)
CA (1)	CA2101164C (lv)
CZ (1)	CZ280847B6 (lv)
DE (2)	DE4101873C2 (lv)
DK (1)	DK0568577T3 (lv)
EE (1)	EE03016B1 (lv)
ES (1)	ES2098496T3 (lv)
FI (1)	FI101040B (lv)
GR (1)	GR3022993T3 (lv)
LT (1)	LT3659B (lv)
LV (1)	LV11103B (lv)
NO (1)	NO304638B1 (lv)
RO (1)	RO114737B1 (lv)
RU (1)	RU2114619C1 (lv)
SK (1)	SK278736B6 (lv)
UA (1)	UA27848C2 (lv)
WO (1)	WO1992012710A1 (lv)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6756056B2 (en) *	1997-04-08	2004-06-29	Alan A. Rubin	Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi) *	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
RU2173150C1 (ru) *	2000-06-27	2001-09-10	Васильев Виталий Николаевич	Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
US6531153B2 (en) *	2001-05-29	2003-03-11	Drugtech Corporation	Composition with sustained release of levodopa and carbidopa
CA2461616A1 (en) *	2001-09-28	2003-04-03	Mcneil-Ppc, Inc.	Composite dosage forms having an inlaid portion
EP1560569A4 (en) *	2002-10-11	2006-03-22	Depomed Dev Ltd	GASTRORETENTIVE LEVODOPA DELIVERY FORM
ES2360759T3 (es) *	2003-08-29	2011-06-08	Centocor Ortho Biotech Inc.	Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
US20050070608A1 (en) *	2003-08-29	2005-03-31	Julius Remenar	Pharmaceutical compositions and method of using levodopa and carbidopa
US8815950B2 (en) *	2003-08-29	2014-08-26	Janssen Biotech, Inc.	Pharmaceutical compositions and method of using levodopa and carbidopa
RU2365580C2 (ru) *	2004-06-04	2009-08-27	Ксенопорт, Инк.	Пролекарства леводопа, композиции на их основе и их применения
NZ560826A (en) *	2005-03-28	2009-06-26	Orexo Ab	Composition comprising weak acid and particulate L-dopa useful in the treatment of parkinson's disease
AU2006261893A1 (en) *	2005-06-23	2007-01-04	Combinatorx, Incorporated	Improved dosage forms for movement disorder treatment
US20070275060A1 (en) *	2005-08-05	2007-11-29	Osmotica Costa Rica Sociedad Anonima	Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
AU2007338631A1 (en) *	2006-12-22	2008-07-03	Combinatorx, Incorporated	Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US8377474B2 (en)	2007-12-28	2013-02-19	Impax Laboratories, Inc.	Controlled release formulations of levodopa and uses thereof
EP2233131A1 (en) *	2009-03-23	2010-09-29	Laboratorios Lesvi, S.L.	Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) *	2011-07-15	2013-01-23	한미약품 주식회사	몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
AU2014332024B2 (en)	2013-10-07	2019-09-26	Impax Laboratories, Llc	Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en)	2013-10-07	2021-04-27	Impax Laboratories, Llc	Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (ja) *	2017-08-18	2022-05-13	大原薬品工業株式会社	良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) *	2018-11-13	2020-05-20	日本酢ビ・ポバール株式会社	結合剤
US20210324222A1 (en) *	2018-11-13	2021-10-21	Japan Vam & Poval Co., Ltd.	Binder
JP6694564B1 (ja) *	2018-11-13	2020-05-13	日本酢ビ・ポバール株式会社	結合剤
WO2020100933A1 (ja) *	2018-11-13	2020-05-22	日本酢ビ・ポバール株式会社	結合剤
EP4134103A4 (en) *	2020-04-10	2024-04-24	Japan Vam & Poval Co., Ltd.	BINDER
CN116457077A (zh) *	2020-11-19	2023-07-18	旭化成株式会社	多孔膜
US11986449B2 (en)	2020-12-22	2024-05-21	Amneal Pharmaceuticals Llc	Levodopa dosing regimen
EP4267113A4 (en)	2020-12-22	2025-02-12	Amneal Pharmaceuticals LLC	LEVODOPA DOSING SCHEME

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE631201C (de) *	1932-08-07	1936-06-16	Chemische Forschungs Gmbh	Traegerstoff fuer Arzneimittel
DE748317C (de) *	1941-08-17	1944-12-19	Wacker Chemie Gmbh	Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) *	1967-08-31	1971-06-08	Eisai Co Ltd	Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) *	1968-10-01	1976-05-17	Merck & Co Inc	Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) *	1970-10-01	1973-10-30	Merck & Co Inc	Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en)	1979-04-26	1985-10-16	Merrell Toraude & Co	Alpha-halomethylaminoacids
DE3042916A1 (de) *	1979-06-01	1982-07-01	Joachim 7440 Nürtingen Dudzik	Tablette
CA1218604A (en) *	1981-07-08	1987-03-03	Alec D. Keith	Trinitroglycerol sustained release vehicles and preparations therefrom
US4424235A (en) *	1981-09-14	1984-01-03	Hoffmann-La Roche Inc.	Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de)	1981-09-14	1985-10-31	Hoffmann La Roche	Pharmazeutisches praeparat.
JPS5852219A (ja) *	1981-09-22	1983-03-28	Sumitomo Chem Co Ltd	パ−キンソン病治療剤
EP0147780A3 (en) *	1984-01-03	1987-03-11	Merck & Co. Inc.	Drug delivery device
US4927633A (en) *	1984-03-19	1990-05-22	Alza Corporation	Dispenser for delivering drug to livestock
US4685918A (en) *	1985-02-01	1987-08-11	Merck & Co., Inc.	Lipid osmotic pump
NZ220599A (en) *	1986-06-16	1990-10-26	Merck & Co Inc	Controlled release oral dosage formulation of carbidopa and levodopa
ZA889189B (en) *	1986-06-16	1989-08-30	Merck & Co Inc	Controlled release combination of carbidopa/levodopa
US4832957A (en) *	1987-12-11	1989-05-23	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
US4983400A (en) *	1986-06-16	1991-01-08	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
SE460947B (sv) *	1986-08-26	1989-12-11	Lejus Medical Ab	En multiple-unit-dos komposition av l-dopa
US4940465A (en) *	1987-05-27	1990-07-10	Felix Theeuwes	Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) *	1987-05-27	1990-01-09	Alza Corporation	Juxtaposed laminated arrangement
US4915949A (en) *	1987-07-13	1990-04-10	Alza Corporation	Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) *	1987-08-03	1994-08-23	Gaylen M. Zentner	Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
AU608891B2 (en) *	1987-09-24	1991-04-18	Merck & Co., Inc.	Solubility modulated drug delivery device
US4946686A (en) *	1987-09-24	1990-08-07	Merck & Co., Inc.	Solubility modulated drug delivery system
DE3841955A1 (de) *	1987-12-31	1989-07-13	Asta Pharma Ag	Synergistische kombination von decarboxylasehemmern und l-dopa-pellets
EP0324947B2 (de) *	1987-12-31	1997-08-20	ASTA Medica Aktiengesellschaft	Synergistische Kombination von Decarboxylasehemmern und L-Dopa-Pellets

1991
- 1991-01-23 DE DE4101873A patent/DE4101873C2/de not_active Expired - Lifetime
1992
- 1992-01-23 DK DK92903405.6T patent/DK0568577T3/da active
- 1992-01-23 DE DE59207852T patent/DE59207852D1/de not_active Expired - Lifetime
- 1992-01-23 RU RU93051537/14A patent/RU2114619C1/ru not_active IP Right Cessation
- 1992-01-23 ES ES92903405T patent/ES2098496T3/es not_active Expired - Lifetime
- 1992-01-23 CZ CS923692A patent/CZ280847B6/cs unknown
- 1992-01-23 RO RO93-01024A patent/RO114737B1/ro unknown
- 1992-01-23 JP JP50323992A patent/JP3382940B2/ja not_active Expired - Lifetime
- 1992-01-23 CA CA002101164A patent/CA2101164C/fr not_active Expired - Fee Related
- 1992-01-23 EP EP92903405A patent/EP0568577B1/de not_active Expired - Lifetime
- 1992-01-23 AU AU11868/92A patent/AU658171B2/en not_active Ceased
- 1992-01-23 WO PCT/DE1992/000043 patent/WO1992012710A1/de not_active Ceased
- 1992-01-23 US US08/090,163 patent/US5532274A/en not_active Expired - Lifetime
- 1992-01-23 UA UA94051480A patent/UA27848C2/uk unknown
- 1992-01-23 AT AT92903405T patent/ATE147264T1/de not_active IP Right Cessation
- 1992-01-23 SK SK3692-92A patent/SK278736B6/sk unknown
1993
- 1993-05-14 LT LTIP555A patent/LT3659B/lt not_active IP Right Cessation
- 1993-06-14 LV LVP-93-567A patent/LV11103B/lv unknown
- 1993-06-22 BG BG97894A patent/BG61677B1/bg unknown
- 1993-07-09 NO NO932159A patent/NO304638B1/no not_active IP Right Cessation
- 1993-07-22 FI FI933304A patent/FI101040B/fi active
1994
- 1994-06-29 EE EE9400066A patent/EE03016B1/xx not_active IP Right Cessation
1997
- 1997-04-01 GR GR970400667T patent/GR3022993T3/el unknown

Also Published As

Publication number	Publication date
FI933304A0 (fi)	1993-07-22
EP0568577B1 (de)	1997-01-08
CA2101164A1 (fr)	1992-07-24
BG61677B1 (bg)	1998-03-31
FI101040B (fi)	1998-04-15
ES2098496T3 (es)	1997-05-01
LT3659B (en)	1996-01-25
RU2114619C1 (ru)	1998-07-10
CZ369292A3 (en)	1993-09-15
DK0568577T3 (da)	1997-06-30
WO1992012710A1 (de)	1992-08-06
GR3022993T3 (en)	1997-07-30
FI933304L (fi)	1993-07-22
AU658171B2 (en)	1995-04-06
SK369292A3 (en)	1998-02-04
ATE147264T1 (de)	1997-01-15
JP3382940B2 (ja)	2003-03-04
NO932522L (no)	1993-07-09
DE59207852D1 (de)	1997-02-20
JPH06504543A (ja)	1994-05-26
NO932522D0 (no)	1993-07-09
LV11103B (en)	1996-06-20
SK278736B6 (sk)	1998-02-04
EP0568577A1 (de)	1993-11-10
DE4101873C2 (de)	1993-12-09
RO114737B1 (ro)	1999-07-30
EE03016B1 (et)	1997-08-15
CA2101164C (fr)	2001-04-24
US5532274A (en)	1996-07-02
NO304638B1 (no)	1999-01-25
CZ280847B6 (cs)	1996-04-17
LTIP555A (en)	1994-11-25
BG97894A (bg)	1994-04-29
UA27848C2 (uk)	2000-10-16
DE4101873A1 (de)	1992-07-30
AU1186892A (en)	1992-08-27

Publication	Publication Date	Title
LV11103A (lv)	1996-04-20	Perorali lietojama zalu forma centralas nervu sistemas dofamina deficita stavoklu arstesanai
AP9600868A0 (en)	1996-10-31	Polymer coated tablet comprising amoxycillin and clavulanate.
DK1741426T3 (da)	2008-10-06	Smelteekstruderede oralt administrerbare hydromorphonformuleringer
ATE237330T1 (de)	2003-05-15	Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
KR880000098A (ko)	1988-03-23	콘드로이틴 설페이트 면역자극 조성물
KR960700054A (ko)	1996-01-19	파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
IL117356A (en)	2000-08-31	Controlled release matrix and pharmaceutical compositions for oral administration containing it
AR028299A1 (es)	2003-05-07	Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
GEP20043315B (en)	2004-02-10	Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
KR920702216A (ko)	1992-09-03	아세틸 d-카르니틴의 녹내장 치료에의 용도
IL103303A (en)	1997-06-10	Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
EE04606B1 (et)	2006-04-17	H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
DE69429964D1 (de)	2002-04-04	Feste, therapeutische oder hygienische, mucoadhäsive Zusammensetzung zur Verabreichung durch Auftragen auf der Mund-schleimhaut oder der Nasen-schleimhaut
ATE315399T1 (de)	2006-02-15	Hemmung von systemischen infektionen in menschen und wirbeltieren mit ballaststoffen
KR970025615A (ko)	1997-06-24	암 전이 억제제
US5082665A (en)	1992-01-21	Anti-snoring formulations using yohimbine
FI955837A0 (fi)	1995-12-04	Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
KR940701249A (ko)	1994-05-28	진통제
KR890007728A (ko)	1989-07-05	진통제 제조방법
ES2139774T3 (es)	2000-02-16	Uso de una combinacion de antineoplastones en la preparacion de un medicamento para el tratamiento de la neurofibromatosis.
IT1224250B (it)	1990-09-26	Associzione del depiprazolo con la morfina
KR960003718A (ko)	1996-02-23	말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
HUP0103864A2 (hu)	2002-05-29	3-(1H-4-Imidazolimetil)-indan-5-ol alkalmazása intraspinálisan beadható gyógyszerkészítmények előállítására
RU2002112882A (ru)	2003-12-27	Способ повышения резистентности сухостойных коров
CO5160246A1 (es)	2002-05-30	Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias